Nuriet K. Khuageva

发表

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

D. Esseltine, B. Coiffier, P. Zinzani, 2012, Journal of Hematology & Oncology.

Characterization of haematological parameters with bortezomib–melphalan–prednisone versus melphalan–prednisone in newly diagnosed myeloma, with evaluation of long‐term outcomes and risk of thromboembolic events with use of erythropoiesis‐stimulating agents: analysis of the VISTA trial

D. Esseltine, M. Dimopoulos, P. Richardson, 2011, British journal of haematology.

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.

D. Esseltine, M. Dimopoulos, A. Palumbo, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.

W. Jędrzejczak, H. Dombret, G. Martinelli, 2007, Blood.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Bin Jiang, Ofer Shpilberg, D. Esseltine, 2008, The New England journal of medicine.

MMY-3002: A Phase 3 Study Comparing Bortezomib-Melphalan-Prednisone (VMP) with Melphalan-Prednisone (MP) in Newly Diagnosed Multiple Myeloma.

M. Dimopoulos, A. Palumbo, P. Richardson, 2007 .

Bortezomib–Melphalan–Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study.

M. Dimopoulos, J. Miguel, P. Richardson, 2008 .

Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.

D. Esseltine, M. Dimopoulos, A. Palumbo, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A217 Erythropoiesis-Stimulating Agents: No Impact on Long-Term Outcome in MM Patients in the VISTA Trial

M. Dimopoulos, K. Anderson, P. Richardson, 2009 .

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib–melphalan–prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study

D. Esseltine, M. Dimopoulos, A. Palumbo, 2011, European journal of haematology.

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.

M. Dimopoulos, P. Richardson, H. van de Velde, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prolonged therapy with bortezomib plus melphalan-prednisone (vmp) results in improved quality and duration of response in the phase iii vista study in previously untreated multiple myeloma (mm)

D. Esseltine, M. Dimopoulos, A. Palumbo, 2008 .

Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma

D. Esseltine, M. Dimopoulos, A. Palumbo, 2008 .

Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial.

M. Dimopoulos, J. Miguel, P. Richardson, 2008 .

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

D. Esseltine, M. Dimopoulos, A. Palumbo, 2011 .

Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma

H. Goldschmidt, A. Ho, T. Moehler, 2010, Anti-cancer drugs.

Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.

D. Esseltine, M. Dimopoulos, A. Palumbo, 2009 .

A172 Peripheral Neuropathy with VMP Resolves in the Majority of Patients and Shows a Rate Plateau

M. Dimopoulos, A. Palumbo, J. Miguel, 2009 .

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan–prednisone vs. melphalan–prednisone in the phase III VISTA trial in multiple myeloma

D. Esseltine, H. Goldschmidt, M. Dimopoulos, 2011, European journal of haematology.

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.

W. Jędrzejczak, H. Dombret, G. Martinelli, 2007, Blood.